

Milton Keynes University Hospital NHS Foundation Trust

Questions	Notes/Comments	Response	
		Regimen Name	Total Patients
		Paclitaxel	0
		Gemcitabine	0
		Osimertinib	1
1) 1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non- small cell Lung Cancer (NSCLC) with the mentioned regimen names?	Included are all patients that received the requested chemotherapy between Nov -18 to April -19.	Carboplatin and Pemetrexed	2
		Cisplatin and Pemetrexed	0
		Pembrolizumab monotherapy	26
		Pembrolizumab in combination	0
		Ateolizumab	2
		Nivolumab	0
		Otheractivesystemicanti-	21

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.



Milton Keynes University Hospital NHS Foundation Trust

		cancertherapy	
2 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the mentioned regimen names?	Included are all patients that received the requested chemotherapy between Nov -18 to April -19.	Regimen Name	Total Patients
		Cetuximab not in combination with FOLFIRI or FOLFOX	12
		Cetuximab in combination with FOLFIRI	0
		Cetuximab in combination with FOLFOX	0
		Panitumumab not in combination with FOLFIRI or FOLFOX	0
		Panitumumab in combination with FOLFIRI	0
		Panitumumab in combination with FOLFOX	0
		Nivolumab	0
		Aflibercept	0
		Bevacizumab	0
		Ramucirumab	0
		Regorafenib	0

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.



Milton Keynes University Hospital NHS Foundation Trust

		Sorafenib	0
		Regimen Name	Total Patients
		Cisplatin single agent	0
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Cancer with the following:	Included are all patients that received the requested chemotherapy between Nov -18 to April -19.	Cisplatin in combination with another agent	2
		Carboplatin single agent	0
		Carboplatin in combination with another agent	0
		Nivolumab	0
		Pembrolizumab	0
		Atezolizumab	0

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Chief Executive: Joe Harrison Chairman: Simon Lloyd